Production of a Novel Camel Single-Domain Antibody Specificfor the Type III Mutant EGFR
Authors:
- M.J. RasaeeMRM.J. Rasaee
- H. ModjtahediHMH. Modjtahedi
- M. TaghikhaniMTM. Taghikhani
- 1 January 2004
- journal article
- Published by Springer Nature in Tumor Biology
- Vol. 25 (5-6) , 296-305
Abstract
Camelids have a unique immune system capable of producing single-domain heavy-chain antibodies. The antigen-specific domain of these heavy-chain IgGs (VHH) are the smallest binding units produced by the immune system. In this study, we report the isolation and characterization of several binders against the epidermal growth factor receptor (EGFR) vIII retrieved from immune library of camels (Camelus bactrianus and Camelus dromedarius). The EGFRvIII is a ligand-independent, constitutively active, mutated form of the wild-type EGFR. The expression of EGFRvIII has been demonstrated in a wide range of human malignancies, including gliomas, and breast, prostate, ovarian and lung cancer. Camels were immunized with a synthetic peptide corresponding to a mutated sequence and tissue homogenates. Single-domain antibodies (VHH) were directly selected by panning a phage display library on successively decreasing amounts of synthetic peptide immobilized on magnetic beads. The anti-EGFRvIII camel single-domain antibodies selectively bound to the EGFRvIII peptide and reacted specifically with the immunoaffinity-purified antigen from a non-small cell lung cancer patient. These antibodies with affinities in the nanomolar range recognized the EGFRvIII peptide and affinity-purified mutated receptor. We concluded that using the phage display technique, antigen-specific VHH antibody fragments are readily accessible from the camelids. These antibodies may be good candidates for tumor-diagnostic and therapeutic applications.Keywords
This publication has 26 references indexed in Scilit:
- Production and Characterization of a New Antibody Specific for the Mutant EGF Receptor, EGFRvIII, in Camelus bactrianusTumor Biology, 2004
- Targeting of cells expressing wild‐type EGFR and type‐III mutant EGFR (EGFRvIII) by anti‐EGFR MAb ICR62: A two‐pronged attack for tumour therapyInternational Journal of Cancer, 2003
- Magic bullets hit the targetNature, 2002
- Efficient tumor targeting by single‐domain antibody fragments of camelsInternational Journal of Cancer, 2002
- Monoclonal antibodies and therapy of human cancersBiotechnology Advances, 2000
- Methods for the generation of chicken monoclonal antibody fragments by phage displayJournal of Immunological Methods, 2000
- Phage Display: A Molecular Tool for the Generation of Antibodies— A ReviewPlacenta, 2000
- The Hallmarks of CancerCell, 2000
- Creating and engineering human antibodies for immunotherapyAdvanced Drug Delivery Reviews, 1998
- ‘Camelising’ human antibody fragments: NMR studies on VH domainsFEBS Letters, 1994